Press Releases Detail:
AVITAR’S TECHNOLOGY TO BE USED BY EGYPTIAN GOVERNMENT
ORALscreen® DEPLOYED BY EGYPTIAN MINISTRY OF TOURISM
January 07, 2008
Canton, MA – (BUSINESS WIRE)—Avitar Inc. ("AVTI"), manufacturers of nationally branded oral fluid testing diagnostic devices and customized polyurethane applications used in wound dressings, announced today that the Company’s ORALscreen rapid test for drugs-of-abuse and electronic reader has been approved by the Egyptian Government to be initially deployed by the Ministry of Tourism. Avitar’s random on-site drug screening technology will be used to test all tour bus drivers, travel agents, and related personnel. Peter Phildius, Avitar’s Chairman and CEO said, "Egypt represents a significant business opportunity for Avitar. While we have previously focused our attention on the $1.5B existing market in the United States, we also must recognize the demand for our products world-wide. Egypt’s population of 75 million is growing twice as fast as the US. The ORALscreen program is important to the Egyptian government’s expanding efforts to address substance abuse in its society. Avitar will seize upon this opportunity to increase its reach in overseas markets, which currently represent approximately 10% of sales revenue." Avitar’s positioning as a consultative drug-free workplace technology and services provider, plays a central role in the model for convergence and integration efforts of its Egyptian business partners, the Ministry of Health, the Ministry of Tourism and the Ministry of the Interior. About Avitar, Inc. Avitar Inc. develops, manufactures and markets innovative proprietary products. Markets include fluid diagnostics, disease and clinical testing, and customized applications for wound dressings. Principal products include ORALscreen®, (the first non-invasive, rapid, onsite oral fluid test for drugs-of abuse), and Hydrasorb®, (an absorbent topical dressing for moderate to heavy exudating wounds). Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy. For more information, see Avitar's website at https://avitarinc.com. Avitar Inc. is a fully reporting company whose stock trades on the OTCBB under the symbol "AVTI.OB". For information, contact Investor Relations - Peter Cholakis, VP – Marketing. Forward-Looking Statements This release contains forward-looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company’s actual results could differ materially from those anticipated in such forward-looking statements.